SAB Biotherapeutics (SABS) has released an update to notify the public and investors about a regulation fd disclosure.
On February 2, 2024, the Company issued a press release announcing the appointment of Mr. Reich. The disclosed information in connection with this announcement is not considered legally filed under the Securities Exchange Act of 1934 and should not be assumed to be part of any future securities filings, except if explicitly referenced therein.
For further insights into SABS stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
